Method for establishing TCR-T cells targeting HPV16 related cervical cancer

Abstract

The invention relates to the technical field of medical apparatus and instruments, in particular to a TCR-T cell establishment method for targeting HPV16 related cervical cancer, which comprises the following steps: target selection and prediction: HLA-A subtype sequencing is performed on 140 patients with cervical cancer and precancerous lesions received and treated in the gynecology department of Shenzhen hospitals, the total proportion of HLA A*02: 01, HLA A*24: 02 and HLA A*11: 01 patients is more than 80%, and due to HLA A*02: 01, the research of HLA A*24: 02 can be looked up, HLA A*11: 01 subtype (about 30%) patients with more Chinese populations are mainly selected as vaccine development populations in the research, and protein sequences (GenBank: AAD33252.1, GenBank: AAD33253.1, GenBank: AGM34425.1, GenBank: AGM34461.1) of HPV16 and 18 E6 and E7 are obtained from an NCBI website; selection of specific tumor antigens, expression and pairing of TCR genes, screening of high-affinity TCRs and the like are challenging problems confronted by TCR-T cell application, and are also breakthrough for establishing a TCR-T cell treatment technology.

Description

technical field [0001] The patent of the present invention relates to the technical field of medical devices, specifically a method for establishing TCR-T cells targeting HPV16-related cervical cancer. Background technique [0002] Cervical cancer is a malignant tumor that seriously endangers women's health. There are 520,000 new cases and 260,000 deaths each year worldwide, accounting for the second highest cancer mortality rate among women in the world. Local lesions of early cervical cancer can obtain good curative effect through surgery, radiotherapy or chemotherapy, but for advanced cervical cancer that has metastasized or recurrent cases, the effect of these treatments is not satisfactory, and the 5-year survival rate is only 16.8%. %. How to improve the treatment effect and prolong the survival time of patients has become a huge clinical challenge, and there is an urgent need to develop new treatment models. Studies have shown that persistent high-risk HPV infection...

AI Technical Summary

Problems solved by technology

[0004] The purpose of the patent of the present invention is to provide a method for establishing TCR-T cells targeting HPV16-related cervical cancer, which solves the relatively complicated construction of TCR genes and the limitation of major histocompatibility complex (MHC) in TCR gene expression. It is necessary to identify the α-chain and β-chain subtypes of TCR, and to obtain high-affinity TCR sequences after optimizing the pairing

Images